0000000000261453

AUTHOR

Montse Muñoz

showing 4 related works from this author

Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case–control EpiGEICAM study

2014

BACKGROUND: Although there are solid findings regarding the detrimental effect of alcohol consumption, the existing evidence on the effect of other dietary factors on breast cancer (BC) risk is inconclusive. This study aimed to evaluate the association between dietary patterns and risk of BC in Spanish women, stratifying by menopausal status and tumour subtype, and to compare the results with those of Alternate Healthy Index (AHEI) and Alternate Mediterranean Diet Score (aMED). METHODS: We recruited 1017 incident BC cases and 1017 matched healthy controls of similar age (±5 years) without a history of BC. The association between 'a priori' and 'a posteriori' developed dietary patterns and B…

RiskCancer Researchmedicine.medical_specialtyMediterranean dietEpidemiologyprincipal component analysisdietary patternsTriple Negative Breast NeoplasmsaMEDLower riskDiet MediterraneanMediterranean patternBreast cancermedicinebreast neoplasmsOily fishHumansbusiness.industryAHEIIncidence (epidemiology)IncidenceCase-control studyDietary patternmedicine.diseaseSurgeryOncologyQuartileSpainCase-Control StudiesFemalebusinessDemography
researchProduct

Lower Breast Cancer Risk among Women Following Lifestyle Recommendations: A Case-Control Study in Spain.

2015

Oncologymedicine.medical_specialtyBreast cancerEpidemiologybusiness.industryInternal medicineFamily medicinemedicineCase-control studyGeneral Medicinebusinessmedicine.diseaseInternational Journal of Epidemiology
researchProduct

Finding the right dose of fulvestrant in breast cancer

2012

Fulvestrant is a selective estrogen receptor downregulator, behaving as a complete antagonist. It was initially approved, at a dose of 250 mg, to treat hormone dependant breast cancer in second line setting. However, a series of pharmacological and pre-clinical studies have suggested that a higher dose of 500 mg may be more effective. The present work summarizes and discusses clinical trials that have aimed to test the benefits of administering fulvestrant at a higher dose. The data support the use of a higher, and more possibly, effective dose of the agent.

Clinical Trials as TopicAntineoplastic Agents HormonalDose-Response Relationship DrugEstradiolFulvestrantbusiness.industryAntagonistEstrogen receptorBreast NeoplasmsGeneral MedicinePharmacologymedicine.diseaseEffective dose (pharmacology)Clinical trialSecond lineBreast cancerOncologymedicineHumansFemaleRadiology Nuclear Medicine and imagingbusinessFulvestrantmedicine.drugHormoneCancer Treatment Reviews
researchProduct

Quantitative monoclonal antibody determination of estrogen and progesterone receptors in human breast cancer: correlation with the radioligand method.

1994

To assess the possibility of substituting our routine method (dextran-coated charcoal, DCC) of determining estrogen (ER) and progesterone receptors (PR) for an enzyme immunoassay technique (EIA), we compared the two methods for determination of the two types of receptor in breast cancer specimens. In terms of sample positivity or negativity, the two techniques agreed in 76 of the 82 samples analyzed for ER (92.7%; p0.001), and in 65 out of 75 samples assayed for PR (86.6%; p0.001). Quantitative analysis of the data showed a significant correlation between DCC and EIA for both ER (r = 0.84; p0.0001) and PR (r = 0.77; p0.0001). The results suggest the usefulness of EIA in substituting DCC, al…

Cancer Researchmedicine.medical_specialtymedicine.drug_classMammary glandEstrogen receptorBreast NeoplasmsBiologyMonoclonal antibodyRadioligand AssayInternal medicineProgesterone receptormedicineRadioligandHumansReceptorfungiAntibodies MonoclonalGeneral MedicineRadioligand AssayEndocrinologymedicine.anatomical_structureOncologyReceptors EstrogenEstrogenFemaleReceptors Progesteronehormones hormone substitutes and hormone antagonistsOncology
researchProduct